TY - JOUR
T1 - Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations
AU - Undiagnosed Diseases Network
AU - Rodan, Lance H.
AU - Spillmann, Rebecca C.
AU - Kurata, Harley T.
AU - Lamothe, Shawn M.
AU - Maghera, Jasmine
AU - Jamra, Rami Abou
AU - Alkelai, Anna
AU - Antonarakis, Stylianos E.
AU - Atallah, Isis
AU - Bar-Yosef, Omer
AU - Bilan, Frédéric
AU - Bjorgo, Kathrine
AU - Blanc, Xavier
AU - Van Bogaert, Patrick
AU - Bolkier, Yoav
AU - Burrage, Lindsay C.
AU - Christ, Björn U.
AU - Granadillo, Jorge L.
AU - Dickson, Patricia
AU - Donald, Kirsten A.
AU - Dubourg, Christèle
AU - Eliyahu, Aviva
AU - Emrick, Lisa
AU - Engleman, Kendra
AU - Gonfiantini, Michaela Veronika
AU - Good, Jean Marc
AU - Kalser, Judith
AU - Kloeckner, Chiara
AU - Lachmeijer, Guus
AU - Macchiaiolo, Marina
AU - Nicita, Francesco
AU - Odent, Sylvie
AU - O’Heir, Emily
AU - Ortiz-Gonzalez, Xilma
AU - Pacio-Miguez, Marta
AU - Palomares-Bralo, María
AU - Pena, Loren
AU - Platzer, Konrad
AU - Quinodoz, Mathieu
AU - Ranza, Emmanuelle
AU - Rosenfeld, Jill A.
AU - Roulet-Perez, Eliane
AU - Santani, Avni
AU - Santos-Simarro, Fernando
AU - Pode-Shakked, Ben
AU - Dasari, Surendra
AU - Lanpher, Brendan C.
AU - Lanza, Ian R.
AU - Morava, Eva
AU - Oglesbee, Devin
N1 - Funding Information:
Research reported in this paper was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under award number (s) (U01HG007709 [Baylor College of Medicine] and U01HG007672 [Duke University to V.S.]). Additional funding for this project was under award number 1RO1HD090132-01A1 (Cornell University to G.P.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding was provided by a Canadian Institutes of Health Research Grant (MOP-97988 to H.T.K.), and a Rowland and Muriel Haryett Fellowship (University of Alberta, to S.M.L.) and a fellowship from the Ministry of Education and Research of the Community of Madrid to M.P.M. (B2017/BMD-3721), and microgrant from the Rare Disease Foundation (P.Y.B.A. and H.T.K.). Sequencing and analysis was supported by the National Human Genome Research Institute grants UM1 HG008900 and R01 HG009141. K.A.D., B.C., and E.O. were supported the National Institute of Mental Health U01 MH119689.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.
PY - 2021/10
Y1 - 2021/10
N2 - Purpose: CACNA1C encodes the alpha-1-subunit of a voltage-dependent L-type calcium channel expressed in human heart and brain. Heterozygous variants in CACNA1C have previously been reported in association with Timothy syndrome and long QT syndrome. Several case reports have suggested that CACNA1C variation may also be associated with a primarily neurological phenotype. Methods: We describe 25 individuals from 22 families with heterozygous variants in CACNA1C, who present with predominantly neurological manifestations. Results: Fourteen individuals have de novo, nontruncating variants and present variably with developmental delays, intellectual disability, autism, hypotonia, ataxia, and epilepsy. Functional studies of a subgroup of missense variants via patch clamp experiments demonstrated differential effects on channel function in vitro, including loss of function (p.Leu1408Val), neutral effect (p.Leu614Arg), and gain of function (p.Leu657Phe, p.Leu614Pro). The remaining 11 individuals from eight families have truncating variants in CACNA1C. The majority of these individuals have expressive language deficits, and half have autism. Conclusion: We expand the phenotype associated with CACNA1C variants to include neurodevelopmental abnormalities and epilepsy, in the absence of classic features of Timothy syndrome or long QT syndrome.
AB - Purpose: CACNA1C encodes the alpha-1-subunit of a voltage-dependent L-type calcium channel expressed in human heart and brain. Heterozygous variants in CACNA1C have previously been reported in association with Timothy syndrome and long QT syndrome. Several case reports have suggested that CACNA1C variation may also be associated with a primarily neurological phenotype. Methods: We describe 25 individuals from 22 families with heterozygous variants in CACNA1C, who present with predominantly neurological manifestations. Results: Fourteen individuals have de novo, nontruncating variants and present variably with developmental delays, intellectual disability, autism, hypotonia, ataxia, and epilepsy. Functional studies of a subgroup of missense variants via patch clamp experiments demonstrated differential effects on channel function in vitro, including loss of function (p.Leu1408Val), neutral effect (p.Leu614Arg), and gain of function (p.Leu657Phe, p.Leu614Pro). The remaining 11 individuals from eight families have truncating variants in CACNA1C. The majority of these individuals have expressive language deficits, and half have autism. Conclusion: We expand the phenotype associated with CACNA1C variants to include neurodevelopmental abnormalities and epilepsy, in the absence of classic features of Timothy syndrome or long QT syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85109046823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109046823&partnerID=8YFLogxK
U2 - 10.1038/s41436-021-01232-8
DO - 10.1038/s41436-021-01232-8
M3 - Article
C2 - 34163037
AN - SCOPUS:85109046823
SN - 1098-3600
VL - 23
SP - 1922
EP - 1932
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 10
ER -